Clinical Trial Update: Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

This clinical trial update states a Phase 2 study of Becotatug Vedotin as adjuvant therapy for high-risk Nasopharyngeal Carcinoma, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Becotatug Vedotin

Snippet

Sponsor: Kai Hu | Conditions: Nasopharyngeal Carcinoma (NPC), Locoregionally Advanced Nasopharyngeal Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING